Last month, the U.S. had paused the distribution of Regeneron and Lilly’s treatments and said the halt would continue until new data emerges on their efficacy against Omicron.
U.S. limits use of Regeneron, Eli Lilly COVID-19 antibody treatments amid Omicron spread
